Review Article
Year: 2020 | Month: November | Volume: 10 | Issue: 11 | Pages: 204-210
New Challenge Antiviral Treatment of Corona Virus Disease 2019 (COVID-19) Include Renal Impairment
Yousef .Sawikr1, Khlid G ALqathafy2
1Department of Pharmacology and Toxicology, Faculty of Medicine University of Ajdabiya, Libya.
2Department of Biochemistry, Faculty of Medicine, University of Benghazi, Libya.
Corresponding Author: Yousef .Sawikr
ABSTRACT
In almost every country around the world, the current pandemic of coronavirus disease 2019 (COVID-19) caused by extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has provided unparalleled challenges to healthcare systems. There are currently no effective vaccines or therapeutic agents against the virus that have been developed. Infection prevention and control procedures and supportive treatment, including supplemental oxygen and mechanical ventilator assistance, are part of existing clinical management. The creation of SARS-CoV-2 virology research and clinical evidence indicates a possible list of repurposed medicines with sufficient pharmacological effects and therapeutic effectiveness in the treatment of patients with COVID-19.
Researchers are striving to find a virus-specific antiviral. Several medications have been used in China, such as chloroquine, hydroxychloroquine, lopinavir / ritonavir and favipiravir, and the use of the investigational drug remdesivir for the treatment of COVID-19, with some positive findings to date. This paper summarizes agents that are potentially effective against SARS-CoV-2.
Key words: corona virus disease 2019, COVID-19, Antiviral treatment, renal impairment.